MEDIVIR

First Quarter April 28, 2017

First Quarter Highlights

Transformation to R&D focus

- Redemption program implemented and completed
- Outlicensed Olysio and any future simeprevir-containing products in the Nordics to Janssen for royalties and additional commercial milestones
- Commercial rights to Adasuve in the Nordic region returned to Ferrer
- Christine Lind appointed CEO

Continued progress in R&D proprietary pipeline

 MIV-711 osteoarthritis study final DMC safety review with successful outcome to continue as planned

Total revenues of 17.8 MSEK in Q1

Global net sales of Olysio of USD 22.8m, generating royalties of 13.7 MSEK





Significant events after the first quarter

New CEO, Christine Lind, effective April 1

Additional pipeline advances, including from partners

- Reported positive phase II topline efficacy data for remetinostat in early-stage CTCL
- Phase IIa data presented at EASL by partner J&J on JNJ-4178 (HCV combination including simeprevir) reiterated and extended previously presented efficacy and safety data






R&D Update

REMETINOSTAT CTCL is a orphan blood cancer that affects the skin

Early Stage CTCL: Disease background

- Confined to the skin
- High 5-year survival rates (~85%)
- Patients remain at this stage for extended periods and require long-term treatment
- Significant quality of life issues, especially pruritus (itch)



Patient with CTCL: plaques and patches J Clin Aesthetic Dermatol. 2009;2(6):22–27

Significant quality of life issues for patients with CTCL




REMETINOSTAT Patients & physicians need new treatments for early-stage CTCL

Limitations of current treatments

- Currently approved drugs lack sustained efficacy and/or tolerability and are highly irritating
- No single treatment for long-term use
- Available therapies typically used in rotation

Key unmet needs 1)

- Tolerability
- Efficacy on non-responding lesions
- Reduction of clinically significant pruritus (itch)



"All the agents currently available for topical use in CTCL have significant side effects, due to skin irritation, and hypersensitivity." Pierluigi Porcu, MD, Jefferson

¹⁾ Medivir market research; ²⁾ Treatments with full approval in USA only




REMETINOSTAT

Remetinostat: Positive Phase II efficacy and safety data in early-stage CTCL

Remetinostat designed to achieve better efficacy and tolerability balance

- Approved systemic HDAC inhibitors NOT used in early-stage CTCL
 - Effective on disease, but have significant adverse events
- Remetinostat is a topical HDAC inhibitor
- Designed to be effective but decrease toxicity
 - Stable in skin, but degraded rapidly in blood



Positive phase II data in treatment-experienced patients


Efficacy								
Dose	1% QD	0.5% BID	1% BID					
CAILS* confirmed responses	4/20 (20%)	5/20 (25%)	8/20 (40%)					

Safety

- Highly tolerable
 - No adverse events typically associated with systemic HDAC inhibitors were observed



REMETINOSTAT CTCL: orphan cancer disease with significant market opportunity



¹⁾ Leukemia & Lymphoma Society

³⁾ Competitive treatment pricing. The Medical Letter, Issue 1467, April 27, 2015 and Actelion public information

³⁾ Early-stage patients at expected per patient year price



REMETINOSTAT Manageable phase III clinical development for CTCL

About remetinostat

- HDACs: group of enzymes related to proteases
- Topical HDAC inhibitor

Market Exclusivity

- Expected patent life to around 2034, including extensions
- Remetinostat has orphan drug designation

Program Timing

- Phase II final data reported April 2017
- End of Phase II meeting with FDA
- Phase III start expected 2H 2017
- Potential for launch in 2021

Costs

SEK 405m (\$47m) expected costs to NDA submission over a 3 year period (incl. Phase III study and third party milestones)

"As a topical, skin-specific HDAC inhibitor, remetinostat has the potential to be efficacious and have an improved safety profile compared to other available treatments." Youn Kim, MD, Stanford, California US



MIV-711 Ongoing phase IIa studies in osteoarthritis

Phase IIa progressing as expected

- MIV-711.201 enrollment completed (n=244) end October 2016
- Safety: Final planned MIV-711.201 DMC meeting concluded "continue as planned"
- Phase IIa extension study (MIV-711.202) also on track

About MIV-711

- Cathepsin K (a protease) inhibitor
- Market exclusivity: expected patent life to around 2034, including extensions

Timing

Primary 6 month data expected 3Q'17

 Additional 12 and 6 month data expected 1Q'18

Costs

~SEK 65m (\$7.4m) expected costs to completion of ongoing Phase IIa studies

Medivir expects to partner MIV-711 upon successful Phase IIa data



INI-4178

Phase II data shows JNJ-4178's potential for shortening HCV treatment

JNJ-4178 AL-335 + odalasvir + simeprevir janssen

Interim PIIa data showed 100% SVR12 in patients receiving treatment for as short as six weeks with the triple combination

Cohort #	Simeprevir dose (mg)	Odalasvir dose (mg)	AL-335 dose (mg)	Treatment duration (weeks)	Number (%) with SVR12 or SVR24
1	100 QD	50 QD	400 QD	8	20/20 (100%), SVR24
2		50 QOD	800 QD	8	18/20 (90%), SVR12
3	75 QD	50 QOD	800 QD	8	20/20 (100%), SVR12
4 QD: every day	75 QD	50 QOD	800 QD	6	20/20 (100%), SVR12

QOD: every other day

SVR: sustained virologic response

Further information on the trial planning and conduct can be found on clinicaltrials.gov with identifier NCT02765490.

Status and upcoming milestones

- Phase IIb in non-cirrhotic subjects with HCV fully recruited
 - Efficacy, safety and pharmacokinetics of QD JNJ-4178
 - Hepatitis C virus genotype 1, 2, 4, 5, and 6 infection
 - Six or eight weeks treatment
- JNJ-4178 no longer being developed for genotype 3 infection
- Ongoing phase II study in cirrhotic patients
- Filing for approval expected 2019

Medivir interests

Milestones and royalties, if approved



Financial Summary



Financial Summary

Summary of Group's figures	Q	1	Full Year		
(SEK m)	2017	2016	2016		
Net turnover	17.8	20.6	93.0		
EBITDA	-80.9	-60.7	-300.6		
Operation profit (EBIT)	-85.6	-63.7	-312.4		
Profit/loss before tax	-84.3	-62.9	-307.7		
Basic & Diliuted earnings per share	-3.59	-1.50	-10.50		
Net worth per share	38.93	52.39	64.38		
Cash flow from operating activites	-123.9	-36.8	-180.1		
Liquid assets and ST investments	708.9	1 039.5	1 698,5		

- Net turnover totalled SEK 17.8m (20.6m), of which SEK 13.7m (18.1m) comprised first quarter royalties for simeprevir.
- Personnel costs of non recurring nature impacted the total costs negatively by 10.0m (0)



Result of voluantary share redemption program

- The redemption program comprised a total of 6,738,655 shares and a total of 6,647,060 shares was registered for redemption whereof;
 - 131,589 series A shares and,
 - 6,515,471 series B shares
- An acceptance level of 98.6 per cent
- Cash proceeds of approximately SEK 857.5 million was distributed to the shareholders
- The total number of outstanding shares in Medivir now amount to 20,318,977 shares whereof;
 - 474,769 series A shares and,
 - 19,844,208 series B shares
- The total number of votes amounts to 24,591,898 votes





Deep pipeline with multiple value drivers

Proprietary Pipeline

Diversified from early to late stages of development

Project, Mechanism	Disease area	Discovery	Preclinical	Phase I	Phase II	Phase III	Market
Remetinostat Topical HDAC inhibitor	Cutaneous T-cell lymphoma						
MIV-711 Cathepsin K inhibitor	Osteoarthritis						
Birinapant SMAC mimetic	Solid tumors*			\leq \setminus			
	High-grade serous carcinomas						
MIV-818 Nucleotide DNA polymerase inhibitor	Hepatocellular carcinoma						
MIV-323 Fusion protein inhibitor	RSV-infection						
* Combo with Keytruda™			1				

Proclinical phase

Preclinical phase

Clinical phase

Clinical phase

Partnership Pipeline

Partnerships where they meaningfully enhance project value

nere Ily t	Project	Disease area	Partner	Discovery	Preclinical	Phase I	Phase II	Phase III	Market
	Olysio (simeprevir)	Hepatitis C	Janssen						
	JNJ-4178 AL-335+odalasvir+simeprevir	Hepatitis C	Janssen						
	Xerclear	Labial herpes	GSK and Meda						
	MIV-802, nucleotide NS5B polymerase inhibitor	Hepatitis C	Trek Therapeutics						



Improving life for cancer patients through transformative drugs

www.medivir.com

Ticker: MVIR Exchange: Nasdaq Stockholm

For more information please contact Ola Burmark, CFO (ola.burmark@medivir.com)